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Here we report on a monoclonal antibody (IST-9) which distinguishes between human cellular and plasma 
fibronectin. Using /I-galactosidase-fibronectin fusion proteins expressed in E. coli we have demonstrated that 
this monoclonal antibody is specific for a fibronectin segment (ED) which can be included or omitted from 
the molecule depending on the pattern of splicing of the mRNA precursors. Furthermore, using the same 
fusion proteins we have been able to localize precisely the epitopes of two other monoclonal antibodies (IST- 
1 and IST-2), specific for the heparin-binding domain 5 of fibronectin. 
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1. INTRODUCTION 
Fibronectins (FNs) are high-molecular-mass 
glycoproteins present in a soluble form in plasma 
and other body fluids, and in an insoluble form in 
the extracellular matrices and basement mem- 
branes. FN molecules act as bridges between the 
cell surface and extracellular material. In fact, the 
FN molecules contain a cell-binding site and 
binding sites for collagen, heparin, gangliosides 
and fibrin. Due to their multiple interactions FNs 
play an important role in diverse biological 
phenomena including cell adhesion, cell migration, 
hemostasis and thrombosis, wound healing and the 
ability to induce a more normal phenotype in 
transformed cells [l-S]. 
It has been demonstrated that FN polymorphism 
may be at least partially due to alternative splicing 
schemes in two regions (ED and IIICS) since as 
many as ten different mRNAs may originate from 
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the primary transcript of a single gene 16-131 
localized on chromosome two [14,15]. 
Monoclonal antibodies (Mabs) specific to se- 
quences the expression of which is regulated by the 
alternative splicing of pre-mRNA may represent 
useful tools for studying in vivo the distribution 
and structure-function relationships of the various 
FN isoforms. While Mabs able to distinguish be- 
tween the plasma (plFN) and cellular (cFN) forms 
of FN have been reported [ 16-181, the exact 
localization within the FN molecule of their 
epitopes has never been possible. 
The advent of recombinant DNA technology has 
offered a powerful new tool both for the prepara- 
tion of specific antisera and for the localization of 
epitopes recognized by Mabs. In fact, a recent 
report [19] describes the preparation of a rabbit 
antiserum to rat ED sequence [8,9] using a fusion 
protein as antigen. Here we report on a Mab 
(IST-9) which is specific for cFN and, using fi- 
galactosidase-FN fusion proteins expressed in E. 
cofi, show that the epitope it recognizes is localized 
within the ED sequence [8,9]. 
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2. MATERIALS AND METHODS 
Cultured normal human fibroblast (GM-5659) 
and human fibrosarcoma cell lines (HT-1080) were 
grown in Eagle’s minimum essential medium sup- 
plemented with 10% fetal calf serum (Flow 
Laboratories, Irvine, Scotland), previously deplet- 
ed of bovine FN by passage through a large capaci- 
ty gelatin-Sepharose column. 
FN was purified from human plasma and from 
the conditioned media of the cell lines as in [20,21]. 
Thermolysin (Protease type X, Sigma, St. Louis, 
MO, USA) digestion of FN was performed ac- 
cording to [20] using ‘5 pg/mg of FN for 2 h at 
22°C. SDS-PAGE and immunoblotting were car- 
ried out as in [23]. 
The Mabs IST-1 and IST-2, specific for both 
plFN and cFN, were obtained using plFN as an- 
tigen; they have been shown to react with the 
heparin-binding domain 5 of FN [2 1,221. The Mab 
IST-9, specific for cFN only, was obtained using as 
antigen cFN from the SV40-transformed 
WI38-VA13 cell line using the immunization, 
hybridization and cloning procedures described 
[28]. Construction of recombinant plasmids and 
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expression of ,&galactosidase-FN fusion proteins 
was carried out as described in [24]. 
3. RESULTS 
Fig.1 shows a schematic representation of the 
domain structure of human FN and of the p- 
galactosidase-FN fusion proteins used in this 
study. The fusion protein pXFN-111 contains the 
ED sequence plus 129 amino acids of the cell- 
binding domain 4 at its amino-terminal and 158 
amino acids of the heparin-binding domain 5 at its 
carboxy-terminal. The fusion protein pXFN-154 is 
identical to pXFN-111 except that it lacks the en- 
tire ED sequence. The fusion protein pXFN-4 con- 
tains part of the gelatin-binding domain 2. Fig.2A 
shows the polypeptide patterns on SDS-PAGE of 
undigested and thermolysin-digested FNs from 
human plasma (plFN) and from the tissue culture 
medium of the human fibrosarcoma cell line 
HT-1080 (cFN), and of the three fl-galactosidase 
fusion proteins. Fig.2B-D shows immunoblots of 
SDS-PAGE similar to that shown in fig.lA, and 
probed with the Mabs IST-9, IST-2 and IST-1, 
respectively. The Mab IST-9 (fig.2B) reacts only 
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Fig.1. Schematic representation of the structure of human FN and of the P-galactosidase-FN fusion proteins used in 
this study. ED and IIICS represent he two known regions of variability due to alternative splicing of mRNA precursors. 
The site of specificity of the three Mabs used in this paper are indicated. Also indicated are the three types of internal 
homology [26]. 
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(S). 
-2. (A) 4-18% SDS-PAGE gradient of purified plFN (lane 1); purified cFN (HT1080) (2); plFN digested by 
*molysin (3); cFN digested by thermolysin (4); &galactosidase fusion proteins pXFN-111 (5); pXFN-154 (6); 8- 
tctosidase xpressed by the pEX2 vector (7) and fusion protein pXFN-4 (8). Proteins in lanes 7 and 8 were used as 
ative controls in immunoblot experiments. The values on the right are the molecular masses (in kDa) of the standards 
(B-D) Immunoblot analysis of a ~--IWO SDS-PAGE as in A using the Mabs IST-9 (B), IST-I (C) and IST-2 (D). 
In all experiments an immunoglobulin concentration of 10tgfmI was used. 
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with cFN and with the fusion protein pXFN-111, 
which contains the ED sequence. This Mab reacted 
with cFN at concentrations as low as 1 ag/ml, but 
not with plFN at any concentration tested (from 
0.5 to 5OOpg/ml). The Mab IST-2 (fig.2C) reacts 
only with cFN and plFN, but not with any of the 
fusion proteins tested, even at an immunoglobulin 
concentration as high as 5OO/rg/ml. The Mab 
IST-1 (fig.2D) reacts with plFN, cFN and fusion 
proteins pXFN-111 and pXFN-154. In the reaction 
of Mabs with ,&-galactosidase-FN fusion proteins it 
is possible to observe a major high-molecular-mass 
protein, which represents the entire fusion protein, 
plus a number of lower molecular-mass polypep- 
tides which are degradation products due to the 
presence of proteolytic enzymes in E. coli. 
4. DISCUSSION 
The precise localization of the epitopes recog- 
nized by Mabs within molecules is often very dif- 
ficult. The use of recombinant fusion proteins 
expressed in bacteria may greatly simplify this 
localization. 
Here we report on the localization within the ED 
sequence of human FN of the epitope recognized 
by the Mab IST-9 using ,&galactosidase-FN fusion 
proteins expressed in E. cofi. This Mab has been 
shown to be specific for cFN, but not for plFN, 
both in radioimmunoassay and immunoblot ex- 
periments [29]. It also reacts with the fusion pro- 
tein pXFN-111 which contains the ED sequence 
but does not react with the fusion protein 
pXFN-154 which is identical to pXFN-111 except 
lacking the ED sequence. This result clearly 
demonstrates that the epitope recognized by the 
Mab IST-9 is localized within the ED sequence. 
These data and the observation that this Mab 
reacts only with cFN and not with plFN are consis- 
tent with primary structure studies showing that 
the ED sequence is absent in human plFN [22], and 
with experiments howing that the ED segment $ 
absent in liver mRNA which is the source of plFN 
18,271. 
These fusion proteins also gave us the oppor- 
tunity to more precisely define the epitopes 
recognized by the Mabs IST-1 and IST-2, previous- 
ly localized within the first three type III homology 
repeats of the heparin-binding domain 5 (fig.1) 
[20]. Only the first and part of the second type III 
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homology repeat of domain 5 are present in the fu- 
sion proteins pXFN-111 and pXFN-154, and both 
these proteins react with IST-1 but not with IST-2. 
Thus, the epitope recognized by IST-1 is within the 
first 158 amino acids of domain 5, while that 
recognized by IST-2 should be within the remain- 
ing 112 amino acids. While these two Mabs (IST-1 
and IST-2) may be useful in the precise localization 
of the heparin-binding site, the Mab IST-9 may 
represent a powerful reagent o study the structure- 
function relationship of the different FN isoforms 
as well as their production by different cell types. 
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